Arimoclomol regulatory update

FDA granted Fast Track designation to arimoclomol to treat amyotrophic lateral sclerosis (ALS). Arimoclomol, which has U.S. Orphan Drug designation, is in Phase IIa for the indication. CYTR acquired t...